Progressive Grey Matter Volume Changes in Patients with Schizophrenia over 6 Weeks of Antipsychotic Treatment and Their Relationship to Clinical Improvement.
10.1007/s12264-018-0234-6
- Author:
Xiao ZHANG
1
;
Yuyanan ZHANG
1
;
Jinmin LIAO
1
;
Sisi JIANG
1
;
Jun YAN
1
;
Weihua YUE
1
;
Dai ZHANG
2
;
Hao YAN
3
Author Information
1. Peking University Sixth Hospital/Institute of Mental Health, Beijing, 100191, China.
2. Peking University Sixth Hospital/Institute of Mental Health, Beijing, 100191, China. daizhang@bjmu.edu.cn.
3. Peking University Sixth Hospital/Institute of Mental Health, Beijing, 100191, China. hao_y@bjmu.edu.cn.
- Publication Type:Journal Article
- Keywords:
Biomarker;
Grey matter volume;
Rostral medial frontal cortex;
Schizophrenia;
Treatment response
- MeSH:
Adult;
Antipsychotic Agents;
therapeutic use;
Female;
Frontal Lobe;
diagnostic imaging;
drug effects;
pathology;
Genetic Predisposition to Disease;
Gray Matter;
diagnostic imaging;
drug effects;
pathology;
Humans;
Image Processing, Computer-Assisted;
Longitudinal Studies;
Magnetic Resonance Imaging;
Male;
Organ Size;
Psychiatric Status Rating Scales;
Regression Analysis;
Schizophrenia;
diagnostic imaging;
drug therapy;
genetics;
pathology;
Time Factors;
Treatment Outcome
- From:
Neuroscience Bulletin
2018;34(5):816-826
- CountryChina
- Language:English
-
Abstract:
Cross-sectional and longitudinal studies have identified widespread and progressive grey matter volume (GMV) reductions in schizophrenia, especially in the frontal lobe. In this study, we found a progressive GMV decrease in the rostral medial frontal cortex (rMFC, including the anterior cingulate cortex) in the patient group during a 6-week follow-up of 40 patients with schizophrenia and 31 healthy controls well-matched for age, gender, and education. The higher baseline GMV in the rMFC predicted better improvement in the positive score on the Positive and Negative Syndrome Scale (PANSS), and this might be related to the improved reality-monitoring. Besides, a higher baseline GMV in the posterior rMFC predicted better remission of general symptoms, and a lesser GMV reduction in this region was correlated with better remission of negative symptoms, probably associated with ameliorated self-referential processing and social cognition. Besides, a shorter disease course and higher educational level contributed to better improvement in the general psychopathological PANSS score, and a family history was negatively associated with improvement of the negative and total PANSS scores. These phenomena might be important for understanding the neuropathological mechanisms underlying the symptoms of schizophrenia and for making clinical decisions.
